European Medicines Agency publishes supplementary information on funding for medicine safety studies through Seventh Framework Programme
The European Medicines Agency has published information on research activities on medicine safety that may be funded by the European Commission's Seventh Framework Programme (FP7).
The FP7 is the EU's main instrument for funding research in Europe and is running from 2007 to 2013.
Every year, the European Commission receives a list of research priorities on medicine safety adopted by the Agency's Committee for Medicinal Products for Human Use (CHMP), on the basis of recommendations from its Pharmacovigilance Working Party.
The European Commission recently published its orientation paper for 2013, detailing its priorities for health research in 2013. The priorities include three topics proposed by the CHMP in November 2011:
- Long-term safety effects of antipsychotics in patients with dementia;
- Long-term adverse skeletal effects of bisphosphonates;
- DNA collection and studies on the genetic causes of adverse drug reactions: angiotensin-converting enzyme inhibitor-related angioedema and statin-induced myopathy.
Further details on the background to and the expected scope of the proposed research activities are available under funding for medicine safety studies: European Commission Seventh Framework Programme.